Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 115 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2021;384:18 de febrero. [Ref.ID 103836]
2. Cita con resumen
Weiland N, LaFraniere S, Baker M, Thomas K. 2 Alaska health workers got emergency treatment after receiving Pfizer’s vaccine. N Y Times (Print) 2020:16 de diciembre. [Ref.ID 103820]
4. Cita con resumen
Laidlaw TM, Boyce JA. Aspirin-exacerbated respiratory disease — New prime suspects. N Engl J Med 2016;374:484-8. [Ref.ID 99993]
5.Enlace a cita originalTiene citas relacionadas
Thong BYH, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011;71:684-700. [Ref.ID 90601]
6.Enlace a cita originalTiene citas relacionadas
Arden-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011;71:672-83. [Ref.ID 90600]
7.Enlace a cita originalTiene citas relacionadas
Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol 2011;71:659-71. [Ref.ID 90599]
8.Enlace a cita originalTiene citas relacionadas
Nel L, Eren E. Peri-operative anaphylaxis. Br J Clin Pharmacol 2011;71:647-58. [Ref.ID 90598]
9.Enlace a cita originalTiene citas relacionadas
Frew A. General principles of investigating and managing drug allergy. Br J Clin Pharmacol 2011;71:642-6. [Ref.ID 90597]
10.Tiene citas relacionadas Cita con resumen
Waller DG. Allergy, pseudo-allergy and non-allergy. Br J Clin Pharmacol 2011;71:637-8. [Ref.ID 90595]
11. Cita con resumen
Anónimo. What are excipients doing in medicinal products?. Drug Ther Bull 2009;47:81-4. [Ref.ID 86136]
12.Tiene citas relacionadas Cita con resumen
Austen F, Woodcock J, Sasisekharan R. Contaminated heparin. The authors reply. N Engl J Med 2008;359:1293. [Ref.ID 83990]
13.Tiene citas relacionadas Cita con resumen
Kakkar AK, Bonnefoi M. Contaminated heparin. N Engl J Med 2008;359:1292. [Ref.ID 83989]
14.Tiene citas relacionadas Cita con resumen
Greinacher A, Warkentin TE. Contaminated heparin. N Engl J Med 2008;359:1291-2. [Ref.ID 83988]
15. Cita con resumen
Lapi F, Cecchi E, Pedone C, Attanasio F, Banchelli G, Vannacci A, Di Pirro M, Moschini M, Berni V, Matucci R, Cini E, Scalia A, Tendi E, Mugelli A. Safety aspects of iodinated contrast media related to their psychochemical properties: a pharmacoepidemiology study in two Tuscany hospitals. Eur J Clin Pharmacol 2008;64:723-37. [Ref.ID 83517]
16.Tiene citas relacionadas
Schwartz LB. Heparin comes clean. N Engl J Med 2008;358:2505-9. [Ref.ID 83135]
17.Tiene citas relacionadas
Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67. [Ref.ID 83131]
18.Tiene citas relacionadas Cita con resumen
Avorn J. Coagulation and adulteration - Building on science and policy lessons from 1905. N Engl J Med 2008;358:2429-31. [Ref.ID 83129]
19.
Anónimo. Pegaptanib. Reports of anaphylaxis/anaphylactoid reactions. USA. WHO Pharmaceuticals Newsletter 2006;3:2. [Ref.ID 77497]
20. Cita con resumen
Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 2000;356:1505-11. [Ref.ID 53693]
Seleccionar todas
 
 1 a 20 de 115 siguiente >>